Nature, Published online: 03 November 2026; doi:10.1038/d41586-026-03504-2
Physicians were excited about several therapies that slash levels of lipoprotein(a) — an important cardiovascular risk factor. One major trial failed to show a benefit, and now scientists are scrambling to work out what that means.General
This cholesterol drug promised to be a game-changer. Why did it flop in the clinic — and is there still hope?
Nature News0 views
Source:https://www.nature.com/articles/d41586-026-03504-2
PreviousWill AI grant reviews make science more conservative?NextDaily briefing: ‘A triumph of scientific self-correction’
Related posts
GIJN Guide to Investigating Foreign Lobbying
0Hacker News New
Study estimates 75% of NFL players who died over 15-year span had CTE
0Hacker News New
No Brother of Mine Will Play the Flute
0Hacker News New
The Model Has No Arms and Legs – can we stop the marketing hype?
0Hacker News New
Bear turns 10, and it still feels like day one
0Hacker News New
Show HN: HackerChurn – which SaaS tools HN wants to cancel
0Hacker News New